Fig 1: Fibronectin (FN) levels in plasma in the test set using two types of enzyme-linked immunosorbent assays (ELISA) in test setA. FN levels on circulating extracellular vesicles in plasma using Method 1. B. FN levels in plasma using Method 2. C. CD63 levels in plasma. All data were obtained using samples from the same subjects. Healthy controls (HC), n = 30; non-cancerous diseases (Non-C), n = 30; benign breast tumors (bB), n = 20; breast cancer (BC), n = 150; early-stage breast cancer (early-BC), n = 119; after surgery (AS), n = 40. The black horizontal lines are means, and error bars are standard errors.
Fig 2: Fibronectin (FN) levels in plasma in the validation set using two types of enzyme-linked immunosorbent assays (ELISA) in validation setA. FN levels on circulating EVs in plasma using Method 1. B. FN levels in plasma using Method 2. C. CD63 levels in plasma. All data were obtained using samples from the same subjects. Healthy controls (HC), n = 40; non-cancerous diseases (Non-C), n = 50; benign breast tumors (bB), n = 35; breast cancer (BC), n = 90; early-stage breast cancer (early-BC), n = 57. The black horizontal lines are means, and error bars are SEs.
Supplier Page from Novus Biologicals, a Bio-Techne Brand for Recombinant Human CD63 Protein